Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Goldman Sachs downgrades Ryanair to 'neutral'

(Sharecast News) - Goldman Sachs downgraded Ryanair on Monday to 'neutral' from 'buy' and cut the price target to €27.5 from €29.5. The bank said its investment case on the budget airline going into 2025 was based on two main factors.

Firstly, that the stock would see FY26 earnings per share upgrades largely driven by a larger negative OTA (Online Travel Agents) impact in FY25 than consensus had factored in. Secondly, that there was a high likelihood of the PE re-rating from low levels on the removal of ownership restrictions.

"As these catalysts have largely played out we now have a less differentiated/slightly more cautious earnings view relative to (Bloomberg/Visible Alpha Consensus Data) consensus...while the valuation has normalised from low levels," it said.

Goldman said that in terms of estimates, it now sees the outlook as more mixed relative to consensus.

"Looking at FQ2 (upcoming report) we forecast €1.63bn net profit versus consensus of around €1.7bn, while for FY26 overall our forecast is broadly in line around €2.2bn.

"This reflects on the one hand slightly softer fare data for summer than we had previously anticipated coupled with higher SAF (Sustainable Aviation Fuel) costs than we had previously modelled; on the other hand consensus for the winter quarters FQ3+4 looks like a low bar to us, offsetting our slightly lower FQ2 forecast for FY26 overall."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.